news > tag > tc-99m

Can nuclear medicine avoid another Mo-99 shortage?

David T. Drummond ⎜Jun 11, 2018 ⎜ Industry

By Wayne Forrest, AuntMinnie.com staff writer.

Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)

Tags:

99mTc-maraciclatide SPECT for prostate cancer bone metastases

Kevin Yang ⎜Mar 12, 2018 ⎜ Industry

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)

Tags:

isoSolutions supplier IRE is proud to announce a partnership with ASML

David T. Drummond ⎜Feb 1, 2018 ⎜ Products

IRE is proud to announce a partnership with ASML to further develop a new, non-fission production method for medical isotopes such as Mo-99/Tc-99m. This partnership has resulted in the start of the LightHouse Isotopes BV, an ambitious initiative for the development of a promising alternative production method for a sustainable long term supply of Mo-99.

Click here to see full post.

Tags:

isoSolutions Customers Announce Medical Isotope Breakthrough

David T. Drummond ⎜Jan 20, 2015 ⎜ Company

Using equipment supplied by isoSolutions, researchers at four Canadian facilities announced success in the production of Technetium-99m, the workhorse of nuclear medicine, in medical cyclotrons. An interdisciplinary team made up of researchers from TRIUMF, the BC Cancer Agency, the Centre for Probe Development and Commercialization, and Lawson Health Research Institute announced their findings at triumf.ca.

These four research institutions are customers of isoSolutions and the development of this production process was performed on Trasis Mini-All-in-One Automated Synthesis Modules. The Mini-AIO is an automated instrument dedicated to the labeling of tracers with short life-time radioactive isotopes used in diagnostics and therapeutics. It addresses the needs of pharmaceutical production centers as well as of hospitals and research centers. Trasis All-in-One modules are distributed in Canada and Latin America by isoSolutions.

David Drummond, Managing Director of isoSolutions, stated: “We congratulate our customers for this exciting success and we are pleased that one of our products played a role in the project.”

About isoSolutions Marketing & Management Inc.

More information on the company can be found at isoSolutions.

Tags: